Patents Represented by Attorney E. Jay Wilusz
  • Patent number: 7262209
    Abstract: The invention relates to compounds of the general formula wherein Ar1, Ar2, R4, R5, R6, R7, R8, W, X, a and b have the significances given in the specification, and optionally the enantiomers thereof. The active ingredients have advantageous pesticidal properties. They are especially suitable for controlling parasites on warm-blooded animals.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: August 28, 2007
    Assignee: Novartis Animal Health US, Inc.
    Inventors: Thomas Goebel, Pierre Ducray
  • Patent number: 7201910
    Abstract: The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof, or substantially homologous sequences. These nucleic acid sequences are transcripted and translated into peptide sequences which are incorporated into a vaccination strategy to induce and immune response to the surface antigens of ISAV and therefore ISAV itself. Therefore both the use of a vaccine against ISAV, and the incorporation of peptide sequences is herein described.
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: April 10, 2007
    Assignees: Novartis AG, Ottawa Health Research Institute
    Inventors: Steven G Griffiths, Rachael J Ritchie
  • Patent number: 7199108
    Abstract: The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof, or substantially homologous sequences. These nucleic acid sequences are transcripted and translated into peptide sequences which are incorporated into a vaccination strategy to induce and immune response to the surface antigens of ISAV and therefore ISAV itself. Therefore both the use of a vaccine against ISAV, and the incorporation of peptide sequences is herein described.
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: April 3, 2007
    Assignees: Novartis AG, Ottawa Health Research Institute
    Inventors: Steven G Griffiths, Rachael J Ritchie, Joel Heppell
  • Patent number: 7057016
    Abstract: The present invention relates to a folding process for the preparation of biologically active, dimeric, TGF-? (Transforming Growth Factor type ?)-like protein in a detergent-free folding buffer.
    Type: Grant
    Filed: March 20, 2001
    Date of Patent: June 6, 2006
    Assignee: Novartis Corporation
    Inventor: Nico Cerletti
  • Patent number: 6964960
    Abstract: The invention provides compounds of formula (I) wherein R is as defined in the description, and the preparation thereof. The compounds of formula (I) are useful as pharmaceuticals, for use in the treatment of any state associated with high levels of activeted PARP.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: November 15, 2005
    Assignee: Novartis AG
    Inventors: Kaspar Zimmermann, Robert Portmann, Dean Franklin Rigel
  • Patent number: 6949257
    Abstract: Spontaneously dispersible pharmaceutical compositions comprising a piperidine, e.g. 1-acylpiperidine Substance P Antagonist and its use in the treatment of CNS disorders, e.g. depression and social phobia, and respiratory diseases, e.g. asthma and chronic bronchitis.
    Type: Grant
    Filed: March 4, 2003
    Date of Patent: September 27, 2005
    Assignee: Novartis AG
    Inventors: Steffen Lang, Kurt Liechti
  • Patent number: 6930188
    Abstract: A stable solid hydrate of a muscarinic receptor antagonist is useful in the treatment of irritable bowel syndrome, diverticular disease, oesophageal achalasia, chronic obstructive airways disease, over active bladder (including symptoms of incontinence, urge and frequency), urinary incontinence, neurogenic urinary urgency or pollakiuria, treatment of bladder functional disorder, urinary leakage, painful or difficult urination caused by neurogenic bladder, spastic or hypertonic bladder, dysfunctional bladder syndrome, gastrointestinal disorders including gastrointestinal hyperactivity, and relaxing effect on intestinal smooth muscle cells.
    Type: Grant
    Filed: March 25, 2003
    Date of Patent: August 16, 2005
    Assignee: Novartis International Pharmaceutical, Ltd.
    Inventors: Peter James Dunn, John George Matthews, Trevor Jack Newbury, Garry O'Connor
  • Patent number: 6919336
    Abstract: Compounds of formula I and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof wherein the symbols are as defined are MAP kinase inhibitors, useful pharmaceutically for treating TNF? and IL-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: July 19, 2005
    Assignee: Novartis AG
    Inventor: Lászlo Révész
  • Patent number: 6887978
    Abstract: The isolated nucleic acid encoding human vanilloid receptor, said receptor, its preparation, cells expressing said receptor and an assay for testing compounds for their potential to decrease pain in humans. The receptor is involved in detection of noxious stimuli in mammalian organisms.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: May 3, 2005
    Assignee: Novartis AG
    Inventors: Peter McIntyre, Iain Fraser James
  • Patent number: 6780861
    Abstract: The invention provides compounds of formula (I) wherein n, A, R1, R2 and R3 are as defined in the description, and the preparation thereof. The compounds of formula (I) are useful as pharmaceuticals.
    Type: Grant
    Filed: October 31, 2002
    Date of Patent: August 24, 2004
    Assignee: Novartis AG
    Inventor: Joachim Nozulak
  • Patent number: 6649168
    Abstract: This invention provides pharmaceutical compositions comprising TGF-&bgr;.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: November 18, 2003
    Assignee: Novartis AG
    Inventors: Tudor Arvinte, Uwe Thomas Schote, Juergen Sigg
  • Patent number: 6488027
    Abstract: This invention relates to single dose dry powder inhalers in which medicament is stored in a capsule and is released by piercing the capsule wall with polymer-coated steel pins. Methods of preparation of polymer-coated piercing means and their use in releasing the medicament from the capsule are described.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: December 3, 2002
    Assignee: Novartis AG
    Inventor: Claude Moulin